Veterinary Cardiopulmonary Resuscitation: Drug Protocols and Dosing

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Epinephrine (0.01 mg/kg IV/IO) is the first-line vasopressor, administered every 3-5 minutes to improve coronary perfusion pressure. High-dose epinephrine (0.1 mg/kg) is reserved for refractory arrest or anaphylaxis.
• Vasopressin (0.8 U/kg IV/IO) can be substituted for the first or second dose of epinephrine, offering an alternative mechanism of vasoconstriction independent of adrenergic pathways, particularly useful in acidotic states.
• Atropine (0.04 mg/kg IV/IO) is indicated for asystole or bradycardic arrest due to increased vagal tone, but is not recommended for ventricular fibrillation or pulseless ventricular tachycardia.
• Intravenous lipid emulsion (ILE) is a rescue therapy for arrest secondary to lipophilic drug toxicosis, administered as a 1.5 mL/kg bolus of 20% emulsion.
• Sodium bicarbonate (1 mEq/kg IV) is not routinely recommended and is reserved for prolonged arrest, documented severe acidosis, or specific toxicities like tricyclic antidepressant overdose.
• Vascular access (IV or IO) is prioritized; endotracheal administration is a last resort with unpredictable absorption and requires higher doses (2-3x IV).

This article addresses the pharmacologic management of cardiopulmonary arrest in dogs, cats, and other companion animal species, with emphasis on the drug protocols, doses, routes, and timing that constitute the advanced life support (ALS) component of veterinary CPR. It is written for practicing veterinarians and senior veterinary students who require a structured reference for drug selection and administration during resuscitation. The practical dosing sections that follow in later parts of this article assume familiarity with basic life support (BLS), including chest compressions and ventilation, which are not covered here.

The clinical questions this article answers are direct: which drugs should be given during arrest, at what dose, by which route, and at what point in the resuscitation sequence. It also addresses the evidence base for each drug class, the controversies that remain unresolved, and the species-specific considerations that alter drug selection. The framework used throughout is the RECOVER (Reassessment Campaign on Veterinary Resuscitation) initiative, an evidence-evaluated consensus guideline process published by the Veterinary Emergency and Critical Care Society that has become the standard reference for veterinary CPR protocols RECOVER Initiative Veterinary CPR Guidelines.

At a Glance

Physiologic Basis of Drug Therapy During Arrest

Cardiac arrest produces a state of global ischemia in which drug pharmacokinetics are profoundly altered. Blood flow during CPR is a fraction of normal cardiac output, and the distribution of administered drugs depends on the quality of compressions, the duration of arrest, and the patency of the venous system. Drugs given during arrest do not reach their target receptors in predictable concentrations, which is why repeated dosing and dose escalation are built into resuscitation protocols.

Coronary perfusion pressure, the difference between aortic diastolic pressure and right atrial pressure, is the primary hemodynamic determinant of return of spontaneous circulation (ROSC). Vasopressors are administered during CPR specifically to raise aortic diastolic pressure and thereby improve coronary perfusion. Experimental work in swine has demonstrated that the probability of ROSC declines as the time to first drug administration increases, and that a drug combination including epinephrine and vasopressin can achieve 50% ROSC rates even when first drug delivery is delayed to approximately 14 minutes Association of delay to first intervention with return of spontaneous circulation in a swine model of cardiac arrest. These findings underscore that drug timing matters, but they also show that no single agent reliably restores circulation once arrest is prolonged.

The hemodynamic effects of anesthetic protocols used in experimental CPR models vary widely, with reported pre-arrest mean arterial pressures ranging from 68 to 130 mm Hg depending on the agents chosen Survey of effects of anesthesia protocols on hemodynamic variables in porcine cardiopulmonary resuscitation laboratory models before induction of cardiac arrest. This variability complicates extrapolation of experimental drug data to clinical patients and reinforces the need for protocol-driven, instead of anecdotal, drug selection.

Vasopressors

Epinephrine

Epinephrine remains the first-line vasopressor in veterinary CPR. At standard doses, its alpha-adrenergic effects produce peripheral vasoconstriction, which raises aortic diastolic pressure and improves coronary and cerebral perfusion during chest compressions. Beta-adrenergic effects increase myocardial contractility and heart rate, though these effects also increase myocardial oxygen demand and may predispose to post-ROSC arrhythmias.

The RECOVER guidelines recommend epinephrine at 0.01 mg/kg IV or IO, repeated every 3 to 5 minutes throughout the arrest RECOVER Initiative Veterinary CPR Guidelines. High-dose epinephrine, 0.1 mg/kg, is reserved for specific circumstances, including refractory arrest and arrest secondary to anaphylaxis. Experimental data from swine show that high-dose epinephrine improves ROSC rates compared with standard-dose protocols, but the same data demonstrate that the drug combination of epinephrine, vasopressin, and a beta-blocker outperforms either epinephrine strategy alone Association of delay to first intervention with return of spontaneous circulation in a swine model of cardiac arrest. This suggests that the optimal vasopressor strategy may involve more than simple dose escalation.

Vasopressin

Vasopressin produces vasoconstriction through V1 receptors independent of adrenergic pathways, which makes it a rational alternative or adjunct to epinephrine. It is not degraded by the acidotic conditions that accompany prolonged arrest, a theoretical advantage over catecholamines. The RECOVER guidelines permit vasopressin at 0.8 U/kg IV or IO as a substitute for the first or second dose of epinephrine RECOVER Initiative Veterinary CPR Guidelines. Evidence for superiority over epinephrine is lacking, and the choice between the two agents is often guided by availability and clinician preference.

Anticholinergics

Atropine is indicated for arrest rhythms associated with increased vagal tone, particularly asystole and pulseless electrical activity with a bradycardic rate. The recommended dose is 0.04 mg/kg IV or IO, and it may be repeated once if there is no response. Atropine is not recommended for ventricular fibrillation or pulseless ventricular tachycardia, where it has no mechanistic role. The evidence base for atropine in veterinary arrest is limited, and its use is based largely on extrapolation from human protocols and physiologic reasoning.

Reversal Agents and Antidotes

When arrest is suspected to result from drug toxicity, specific reversal agents take priority over standard vasopressor therapy. Naloxone at 0.04 mg/kg IV or IO is indicated for opioid-induced respiratory arrest or bradyarrhythmia. Flumazenil may be considered for benzodiazepine-associated arrest, though its use in veterinary patients is less well standardized.

Intravenous lipid emulsion (ILE) has emerged as a rescue therapy for arrest secondary to lipophilic drug toxicosis, particularly local anesthetics and certain psychotropic medications. The proposed mechanism involves creation of a lipid sink that sequesters lipophilic drugs from target tissues, as well as direct metabolic effects on myocardial fatty acid utilization. Clinical reports in veterinary medicine document successful use of ILE in cases of local anesthetic and other lipophilic drug toxicoses, particularly when cardiopulmonary arrest has occurred and standard resuscitation has failed The use of intravenous lipid emulsion as an antidote in veterinary toxicology. The recommended approach is a 1.5 mL/kg bolus of 20% lipid emulsion administered IV, followed by a continuous infusion. ILE therapy appears to be safe in most patients, but it is warranted only for toxicoses involving fat-soluble agents, not as a routine component of arrest management.

Buffer Therapy

Sodium bicarbonate is no longer recommended as a routine component of CPR. The rationale for its historical use was correction of metabolic acidosis, but the evidence for improved outcomes is mixed. A randomized canine model of ventricular fibrillation arrest found that bicarbonate therapy improved neurologic outcome compared with untreated acidosis, but the effect was modest and the treatment group received additional doses to correct base deficit to a target of -5 mmol/L Sodium bicarbonate may improve outcome in dogs with brief or prolonged cardiac arrest. The RECOVER guidelines recommend bicarbonate only in cases of prolonged arrest, severe pre-existing acidosis, or specific toxicities such as tricyclic antidepressant overdose. When used, the dose is 1 mEq/kg IV, and subsequent dosing should be guided by blood gas analysis instead of empiric administration.

Drug Administration Routes

Vascular access is the priority during arrest. The IV route is preferred, and the IO route is an acceptable alternative when venous access cannot be obtained quickly. Intraosseous catheters placed in the proximal humerus or proximal tibia provide rapid access to the central circulation and are appropriate for all resuscitation drugs. Endotracheal administration is a last resort, used only when neither IV nor IO access is available. Drugs that can be given endotracheally include epinephrine, atropine, and lidocaine, but absorption is unpredictable and the recommended endotracheal dose is generally two to three times the IV dose. The RECOVER guidelines emphasize that endotracheal drug administration is inferior to vascular access and should not delay placement of an IO catheter RECOVER Initiative Veterinary CPR Guidelines.

Fluid Therapy During Arrest

Routine fluid boluses are not recommended during CPR unless there is evidence of hypovolemia. Excessive fluid administration can increase right atrial pressure, which lowers coronary perfusion pressure and worsens resuscitation outcomes. The AAHA and AAFP fluid therapy guidelines emphasize that fluid selection and rate planning should be individualized, and that resuscitation fluids should be administered only when the clinical picture supports volume depletion AAHA/AAFP Fluid Therapy Guidelines for Dogs and Cats. In arrest secondary to hemorrhage or severe dehydration, a rapid bolus of isotonic crystalloid or colloid may be appropriate, but the goal is restoration of perfusion without raising central venous pressure excessively.

Drug Selection by Arrest Phase

The arrest is not a static event. Drug selection should track the phase of resuscitation: the initial electrical phase, the circulatory phase, and the metabolic phase. The RECOVER Initiative guidelines organize advanced life support around these phases and assign drug recommendations accordingly (RECOVER Initiative Veterinary CPR Guidelines).

During the first two minutes, the priority is defibrillation for shockable rhythms and high-quality compressions. Drug therapy begins after the first defibrillation attempt fails or when the rhythm is nonshockable. Epinephrine is the first-line vasopressor in both dogs and cats. Vasopressin is a second-line agent and may be considered when epinephrine alone has not achieved return of spontaneous circulation (ROSC). The evidence for vasopressin comes largely from experimental models, where it has been combined with epinephrine and other agents to improve ROSC rates (Association of delay to first intervention with return of spontaneous circulation in a swine model of cardiac arrest).

The metabolic phase begins after roughly ten minutes of arrest. Acidemia worsens, receptor responsiveness declines, and the probability of ROSC falls steeply with each minute of delay to drug administration. The same swine model demonstrated that the time to first drug administration was an independent predictor of ROSC, with 50% ROSC occurring at a first drug time of 14.1 minutes in the group receiving a drug cocktail (Association of delay to first intervention with return of spontaneous circulation in a swine model of cardiac arrest). This does not mean drugs are futile after that point, but it does mean the team should escalate therapy instead of repeat the same interventions.

Epinephrine Dosing Strategy

Epinephrine remains the primary vasopressor. The standard dose is 0.01 mg/kg intravenously or intraosseously, repeated every three to five minutes during the arrest. High-dose epinephrine, defined as 0.1 mg/kg, has been studied extensively in experimental models. The swine data show that high-dose epinephrine improves ROSC compared with standard-dose protocols, but the same data also show that no single drug improves survival after cardiac arrest (Association of delay to first intervention with return of spontaneous circulation in a swine model of cardiac arrest).

In clinical veterinary practice, high-dose epinephrine is reserved for cases refractory to standard-dose therapy. The rationale is that high-dose epinephrine produces more profound vasoconstriction, which raises coronary perfusion pressure but also increases myocardial oxygen demand and the risk of post-ROSC arrhythmias. Current formulary references should be consulted for species-specific dosing, and the dose should be calculated from the patient's body weight before the arrest begins.

Vasopressin as an Alternative or Adjunct

Vasopressin is a direct vasoconstrictor that acts on V1 receptors and does not rely on beta-adrenergic receptor function. This makes it theoretically useful in patients with severe acidemia, where catecholamine receptor affinity is reduced. The dose is 0.4 U/kg intravenously or intraosseously, given once. It may be repeated once after three to five minutes if ROSC has not occurred.

The evidence base for vasopressin in veterinary CPR is limited. Experimental models have combined vasopressin with epinephrine and other agents, and these combinations have been associated with improved ROSC compared with epinephrine alone (Association of delay to first intervention with return of spontaneous circulation in a swine model of cardiac arrest). However, these are laboratory models, not clinical trials, and the translation to clinical patients is uncertain. Vasopressin should not replace epinephrine as the first-line agent.

Anticholinergics and Their Limited Role

Atropine is included in most CPR algorithms, but its role is narrow. It is indicated for arrest associated with vagally mediated bradycardia or high-grade atrioventricular block. It has no demonstrated benefit in ventricular fibrillation or pulseless electrical activity. The dose is 0.04 mg/kg intravenously or intraosseously, and it may be repeated once.

The canine model that evaluated sodium bicarbonate also used atropine as part of the resuscitation protocol, but the study was not designed to isolate the effect of atropine (Sodium bicarbonate may improve outcome in dogs with brief or prolonged cardiac arrest). In practice, atropine is given early in the code when the rhythm is bradyasystolic, and it is not repeated more than twice.

Buffer Therapy and the Bicarbonate Question

Sodium bicarbonate is no longer administered routinely during CPR. The RECOVER guidelines recommend against its routine use, and this aligns with human resuscitation guidelines. The concern is that bicarbonate generates carbon dioxide, which diffuses into cells and can worsen intracellular acidosis. It also causes a left shift in the oxyhemoglobin dissociation curve, which impairs oxygen delivery to tissues.

The canine model that examined bicarbonate therapy found that dogs receiving bicarbonate had improved outcomes compared with controls, but the study was small and the protocol included aggressive correction of base deficit to -5 mmol/L (Sodium bicarbonate may improve outcome in dogs with brief or prolonged cardiac arrest). This is not the same as giving a fixed dose to every patient. Bicarbonate is reserved for prolonged arrest, severe pre-existing metabolic acidosis, hyperkalemia, or tricyclic antidepressant toxicity. When used, the dose is 1 mEq/kg given slowly, and subsequent doses are guided by blood gas analysis.

Drug Administration Routes and Timing

The intravenous route is preferred, and the intraosseous route is an acceptable alternative when venous access is not available. Intracardiac injection is not recommended. Endotracheal administration is a last resort because drug absorption is unpredictable and the optimal dose is not established.

Drugs should be given as boluses during compressions, followed by a flush of saline to push the drug into the central circulation. The flush volume should be at least 10 mL in dogs and 5 mL in cats. Compressions should continue during drug administration, and the team should not pause compressions to give drugs.

The timeline below outlines the sequence of drug administration during a code.

Fluid Therapy During the Code

Rapid fluid administration is not a treatment for cardiac arrest. It dilutes circulating catecholamines, increases right atrial pressure, and can reduce coronary perfusion pressure. The RECOVER guidelines recommend against routine fluid boluses during CPR. Fluids are given only when hypovolemia is suspected as the cause of arrest, such as with hemorrhage, severe dehydration, or vasodilation from sepsis or anaphylaxis.

When fluids are indicated, isotonic crystalloids are the first choice. The 2024 AAHA/AAFP fluid therapy guidelines emphasize that fluid selection and rate should be individualized to the patient and the suspected cause of arrest (AAHA/AAFP Fluid Therapy Guidelines for Dogs and Cats). A bolus of 10 to 20 mL/kg in dogs and 5 to 10 mL/kg in cats may be given over 10 to 15 minutes, and the patient should be reassessed after each bolus. Colloids are not recommended during CPR.

Species and Setting Considerations

The drug protocols described here apply primarily to dogs and cats. Large animal CPR, including equine and bovine resuscitation, follows different principles. The thoracic anatomy of horses and cattle makes effective external compressions difficult, and the drug doses are not simply scaled from small animal protocols. The MSD Veterinary Manual provides species-specific guidance on emergency drug use and resuscitation (MSD Veterinary Manual, Professional Edition).

In production animal practice, the decision to initiate CPR is influenced by economic factors, prognosis, and welfare considerations. The same drug protocols may be used, but the threshold for starting and stopping resuscitation is different. The World Organization for Animal Health terrestrial standards address animal welfare during emergency procedures, and these should be considered when deciding whether resuscitation is appropriate (WOAH Terrestrial Animal Health Code).

Monitoring Drug Response

The primary endpoint of drug therapy is ROSC, defined as the return of a spontaneous, organized cardiac rhythm with a palpable pulse. Between drug doses, the team should assess the rhythm, the pulse quality during compressions, and the end-tidal carbon dioxide (EtCO2) value. An EtCO2 of 10 to 15 mm Hg during compressions suggests adequate cardiac output. A sudden rise in EtCO2 may indicate ROSC before a pulse is palpable.

Coronary perfusion pressure is the most reliable predictor of ROSC, but it requires arterial catheterization and is rarely available during a code. In its absence, EtCO2 is the best noninvasive surrogate. The team should document the time of each drug administration, the dose given, the route, and the patient's response. This documentation is essential for post-arrest review and for adjusting the protocol in subsequent codes.

Recognized Complications and Failure Modes

The most common complication during veterinary CPR is iatrogenic interruption of chest compressions. Drug preparation, route selection, and administration should never halt compressions for more than a few seconds. The RECOVER Initiative Veterinary CPR Guidelines specify that drug administration should occur during ongoing compressions, with flush volumes delivered rapidly through a proximal catheter port.

Vasopressor overdose produces excessive peripheral vasoconstriction that can reduce coronary perfusion after return of spontaneous circulation. Detect this early by observing a rising end-tidal carbon dioxide (EtCO2) without a palpable pulse, or by noting severe hypertension immediately after ROSC. Capnography remains the most reliable real-time indicator of cardiac output during compressions. A sudden drop in EtCO2 during a code suggests either compressor fatigue, displacement of the endotracheal tube, or a tension pneumothorax.

Buffer therapy complications include hypernatremia, hyperosmolality, and paradoxical intracellular acidosis. The sodium bicarbonate outcome study in canine arrest models demonstrated that bicarbonate administration altered acid-base status but did not uniformly improve neurologic outcome. Detect bicarbonate-related problems by measuring serial blood gases after ROSC and by monitoring serum sodium in patients that survive to the post-arrest period.

Common Errors and Corrective Actions

Less experienced clinicians frequently delay vasopressor administration while attempting vascular access. Peripheral venous access is acceptable, intraosseous access is equivalent for drug delivery and should be placed without delay when veins are collapsed. The swine model of cardiac arrest showed that time to first drug administration independently predicted return of spontaneous circulation, reinforcing the need for rapid, reliable access.

Another recurring error is repeated dosing of epinephrine at escalating intervals without reassessing the underlying rhythm. The RECOVER guidelines recommend a fixed dosing interval, typically every 3 to 5 minutes, with rhythm assessment between doses. Administering additional vasopressors without checking the rhythm wastes time and exposes the patient to cumulative alpha-adrenergic toxicity.

A third error involves giving reversal agents or antidotes without confirming the drug history. For suspected local anesthetic toxicity or lipophilic drug overdose, intravenous lipid emulsion therapy may be indicated, but it should not be given empirically to every arrest patient. Confirm the exposure history, the agent involved, and the time course before committing to lipid emulsion, which carries its own risks including hypertriglyceridemia and interference with concurrent medications.

Limitations of the Evidence

The veterinary CPR evidence base relies heavily on experimental models instead of clinical trials. The porcine CPR laboratory model survey documented that anesthetic protocols before arrest induction produce wide variation in baseline hemodynamics, which complicates extrapolation of drug efficacy data to clinical patients. What works in a healthy laboratory animal under controlled anesthesia may not translate to a critically ill dog or cat with concurrent disease.

Expert opinion still differs on several points. The role of high-dose epinephrine remains contested. Some clinicians advocate higher doses for refractory arrest, while the RECOVER guidelines recommend against routine high-dose epinephrine due to worsened post-resuscitation myocardial function. Vasopressin is no longer universally recommended as a first-line agent, although some clinicians still use it as an adjunct in refractory cases. The Society of Thoracic Surgeons consensus on post-cardiac surgery arrest addresses a human population with specific reversible causes, and its recommendations on early surgical re-exploration do not transfer directly to veterinary patients.

Escalation and Referral

Referral to a specialist is warranted when a patient achieves ROSC and requires ongoing mechanical ventilation, continuous vasopressor infusion, or advanced neurologic monitoring. The post-arrest care phase demands intensive monitoring that general practices may not be equipped to provide. Transfer should occur only after the patient is hemodynamically stable enough to tolerate transport.

Laboratory involvement is indicated for serial blood gas analysis, serum lactate measurement, and electrolyte monitoring during and after the code. Point-of-care analyzers are adequate for intra-arrest decision-making. For toxicology cases, consultation with a veterinary poison control center is appropriate before administering antidotes, particularly for agents where the evidence base is limited to case reports.

Regulatory reporting obligations vary by jurisdiction. Suspected adverse drug reactions, particularly for compounded preparations or extralabel drug use, should be reported through the appropriate national pharmacovigilance system. The AVMA practice resources provide guidance on reporting pathways in the United States, while WOAH terrestrial animal health standards address notifiable disease reporting that may apply if an infectious cause of arrest is suspected.

Troubleshooting Table

Frequently Asked Questions

How should drug dosing be adjusted when a patient is obese or severely underweight?

Dosing for resuscitation drugs should be based on an estimated lean body weight instead of actual body weight in obese patients. Lipophilic drugs such as lidocaine and some reversal agents may distribute into adipose tissue, but the acute hemodynamic effects of epinephrine and vasopressin are best titrated to lean mass to avoid excessive dosing. In severely underweight or dehydrated patients, actual body weight may underestimate the effective circulating volume, so the clinician should use a conservative estimate and reassess response after each dose. Current formulary references provide guidance on body condition scoring and weight adjustment, and the MSD Veterinary Manual offers species-specific dosing considerations that should be consulted before emergency drug administration.

What drug options exist when intravenous access cannot be obtained?

When intravenous access fails, the intraosseous route is the preferred alternative and achieves comparable drug absorption and onset times. Endotracheal administration is a second-line option for epinephrine, atropine, lidocaine, and naloxone, but drug absorption is unpredictable and the required doses are typically two to three times the intravenous dose. Vasopressin and sodium bicarbonate should not be given endotracheally. If intraosseous placement is also impossible, the clinician should continue basic life support while a colleague attempts central venous access. The RECOVER Initiative guidelines specify preferred routes and drug-specific caveats, and these recommendations should be reviewed when designing a crash cart protocol for settings where difficult access is anticipated.

How does the drug protocol differ for a neonatal or pediatric patient?

Neonatal and pediatric patients have higher metabolic rates and different volume of distribution compared to adults, which can alter both the required dose per kilogram and the dosing interval. Epinephrine requirements are often similar on a per-kilogram basis, but the total volume administered must be minimized to avoid fluid overload. Glucose status should be assessed early because hypoglycemia is a common precipitant of arrest in young animals, and dextrose supplementation may be needed alongside standard resuscitation drugs. The RECOVER Initiative provides pediatric-specific considerations within its consensus guidelines, and the MSD Veterinary Manual includes age-related pharmacokinetic notes that are relevant when calculating emergency doses for immature patients.

What should be documented during and immediately after a resuscitation attempt?

Documentation should include the time of arrest recognition, the time of each drug administration with dose and route, the timing of defibrillation attempts, and the patient's rhythm and pulse status at each reassessment interval. Record the total number of epinephrine doses, any buffer therapy given, and the cumulative fluid volume administered. After the event, note the duration of CPR, the time to return of spontaneous circulation if achieved, and any complications such as rib fractures or vascular access failures. This record supports both clinical review and quality improvement efforts. The AVMA practice resources include guidance on medical record standards that apply to emergency procedures, and consistent documentation also supports client communication about the events that occurred.

How should drug selection change in a field or low-resource setting?

In settings where monitoring equipment is limited, the clinician should prioritize drugs with predictable effects and simple dosing schemes. Epinephrine remains the primary vasopressor, and a single concentration prepared in prefilled syringes reduces calculation errors. Vasopressin may be omitted if supply is limited, as its benefit over epinephrine alone is not consistently demonstrated. Atropine should be available but used selectively. Buffer therapy should be deferred unless arrest is prolonged or a known metabolic acidosis exists, because empiric bicarbonate administration without blood gas monitoring carries risk. The RECOVER Initiative guidelines acknowledge that resource constraints require protocol adaptation, and the Society of Thoracic Surgeons consensus on resuscitation similarly emphasizes that drug selection should be guided by the suspected arrest etiology and available monitoring capacity.

How should the clinician explain the use of resuscitation drugs to an owner during an ongoing code?

The clinician should provide a brief, structured update that names the drugs being used, explains their purpose in plain terms, and states the current response to treatment. For example, the owner should be told that epinephrine is being given to support blood pressure and coronary perfusion, and that the team is reassessing the heart rhythm after each drug cycle. The clinician should avoid offering probabilistic outcome statements during the code unless directly asked, and should instead commit to a defined reassessment interval. After the event, a debrief should include which drugs were administered and why, and the discussion should acknowledge the limitations of the evidence base. The RECOVER Initiative materials include client communication guidance that supports this conversation.

Related Clinical & Scientific Guides

• Toxicology in Emergency Practice: Common Poisons and Diagnostic Approach
• Veterinary Cardiopulmonary Resuscitation: Post-Cardiac Arrest Care
• Fluid Therapy Guidelines for Dogs and Cats: A Practical Update

References and Further Reading

• The use of intravenous lipid emulsion as an antidote in veterinary toxicology.. 2011.
• Association of delay to first intervention with return of spontaneous circulation in a swine model of cardiac arrest.. 2007.
• The Society of Thoracic Surgeons Expert Consensus for the Resuscitation of Patients Who Arrest After Cardiac Surgery.. 2017.
• Sodium bicarbonate may improve outcome in dogs with brief or prolonged cardiac arrest.. 1995.
• Survey of effects of anesthesia protocols on hemodynamic variables in porcine cardiopulmonary resuscitation laboratory models before induction of cardiac arrest.. 2000.
• Vital organ blood flow with the impedance threshold device.. 2006.
• RECOVER Initiative Veterinary CPR Guidelines. Veterinary Emergency and Critical Care Society.
• AAHA/AAFP Fluid Therapy Guidelines for Dogs and Cats. AAHA.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Veterinary Emergency Drug Dosing: Weight-Based Calculations
• Veterinary Cardiopulmonary Resuscitation: Post-Cardiac Arrest Care
• Veterinary Crash Cart Organization and Emergency Drug Dosing
• Veterinary Shock: Fluid Resuscitation Strategies
• RECOVER CPR Guidelines: Updates and Practical Implementation

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.